November 5th, 2019

Results from the phase 1-2 clinical trial assessing the benefits of UM171-expanded cord blood transplantation for the treatment of hematological diseases are published in Lancet Hematology.

Ici Radio-Canada – Espoir québécois dans la lutte contre le cancer du sang

La Presse – Une greffe prometteuse pour les gens atteints de cancers du sang 

Montreal Gazette – New leukemia treatment promises astounding results, few side-effects

La Presse –  Personnalité de la semaine : Guy Sauvageau

October 24-26, 2019

The Leucegene team attended the ESH AML conference in Estoril, Portugal.

Click here for Guy Sauvageau’s interview on “why should we target RUNX1 in AML treatment

May 3rd, 2018

Guy Sauvageau, Josée Hébert and the Leucegene team are awarded $12.8 million in funding from Genome Canada and Genome Quebec to continue their work on AML. Click here for more information.